Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle- and differentiation-related molecules in human colon carcinoma cells

International Journal of Oncology

Volumn 28, Issue 5, 2006, Pages 1193-1199

  Suzui, Masumi ^a   Sunagawa, Nao ^a   Chiba, Itaru ^a   Moriwaki, Hisataka ^b   Yoshimi, Naoki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyclic retinoid; Colon cancer; Differentiation; Prevention

Indexed keywords

3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MESSENGER RNA; POLYPRENOIC ACID; PRIMER DNA; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; COLON TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRETINOIN;

EID: 33646851768     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.5.1193     Document Type: Article

References (39)

1. Thaller C and Eichele G: Identification and spatial distribution of retinoids in the developing chick limb bud. Nature 327: 625-628, 1987.
2. Altucci L and Gronemeyer H: The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193, 2001.
3. Sporn MB and Suh N: Chemoprevention of cancer. Carcinogenesis 21: 525-530, 2000.
4. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M and Bisaccia S: Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 23: 5774-5778, 2005.
5. Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA and Sporn MB: Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 8: 3270-3275, 2002.
6. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T and Kojima T: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334: 1561-1567, 1996. (Pubitemid 26177483)
7. Muto Y, Moriwaki H and Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340: 1046-1047, 1999.
8. Takai K, Okun M, Yasuda I, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, Shiratori Y, Muto Y and Moriwaki H: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 48: 39-45, 2005.
9. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohno H and Tanaka T: An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-α expression and cell proliferation. Carcinogenesis 25: 979-985, 2004.
10. Nakamura N, Shidoji Y, Moriwaki H and Muto Y: Apoptosis in human hepatoma cell line induced by 4,5-didehydrogeranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-α. Biochem Biophys Res Commun 219: 100-104, 1996.
11. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL and Moriwaki H: Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24: 1353-1359, 2003.
12. Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagama H, Imawari M, Moriwaki H and Muto Y: Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 10: 151-158, 1994.
13. Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A and Gheber L: Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 93: 338-345, 2005.
14. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A and Bukholm IR: Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 58: 509-514, 2005.
15. Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S and El-Serafi M: Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 4: 22, 2004.
16. Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21: 857-864, 2000.
17. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, Wang S, Weinstein IB and Holt PR: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674, 1996.
18. Arber N, Lightdale C, Rotterdam H, Han KH, Sgambato A, Yap E, Ahsan H, Finegold J, Stevens PD, Green PH, Hibshoosh H, Neugut AI, Holt PR and Weinstein IB: Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 5: 457-459, 1996.
19. Otori K, Sugiyama K, Fukushima S and Esumi H: Expression of the cyclin D1 gene in rat colorectal aberrant crypt foci and tumors induced by azoxymethane. Cancer Lett 140: 99-104, 1999.
20. Paulsen JE, Loberg EM, Olstorn HB, Knutsen H, Steffensen IL and Alexander J: Flat dysplastic aberrant crypt foci are related to tumorigenesis in the colon of azoxymethane-treated rat. Cancer Res 65: 121-129, 2005.
21. CIP1 and inhibition of expression of cyclin D1. Cancer Res 62: 3997-4006, 2002.
22. Shimizu M, Suzui M, Lim JTE and Weinstein IB: Effects of acyclic retinoid on growth, cell cycle control, the EGFR signaling pathway, and gene expression in human squamous cell carcinoma cell lines. Clin Cancer Res 10: 1130-1140, 2004.
23. Suzui M, Shimizu M, Masuda M, Lim JTE, Yoshimi N and Weinstein IB: Acyclic retinoid activates retinoic acid receptor b and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 3: 309-316, 2004.
24. McWilliams RR and Erlichman C: Novel therapeutics in colorectal cancer. Dis Colon Rectum 48: 1632-1650, 2005.
25. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
26. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
27. Suzui M, Inamine M, Kaneshiro T, Morioka T, Yoshimi N, Suzuki R, Kohno H and Tanaka T: Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol 27: 1391-1399, 2005.
28. Matsumoto H, Erickson RH, Gum JR, Yoshioka M, Gum E and Kim YS: Biosynthesis of alkaline phosphatase during differentiation of the human colon cancer cell line Caco-2. Gastroenterology 98: 1199-1207, 1990.
29. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, De Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154: 369-387, 2001.
30. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H and Muto Y: Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, Huh-7. Biochem Biophys Res Commun 207: 382-388, 1995.
31. Muto Y and Moriwaki H: Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 73: 1389-1393, 1984.
32. Um SJ, Kwon YJ, Han HS, Park SH, Park MS, Rho YS and Sin HS: Synthesis and biological activity of novel retinamide and retinoate derivatives. Chem Pharm Bull 52: 501-506, 2004.
33. Um SJ, Han HS, Kwon YJ, Park SH, Rho YS, Sin HS and Park JS: Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int J Cancer 107: 1038-1046, 2003.
34. Landers JE, Cassel SL and George DL: Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568, 1997.
35. Steinman RA, Hofmann B, Iro A, Guillouf C, Liebermann DA and El-Houseini M: Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.
36. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
37. Hong WK and Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073-1077, 1997.
38. Shao RX, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, Kawabe T and Omata M: Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 128: 86-95, 2005.
39. Wong N, Chan KY, Macgregor PF, Lai PB, Squire JA, Beheshti B, Albert M and Leung TW: Transcriptional profiling identifies gene expression changes associated with IFN-α tolerance in hepatitis C-related hepatocellular carcinoma cells. Clin Cancer Res 11: 1319-1326, 2005.